Australia's most trusted
source of pharma news
Wednesday, 16 April 2025
Posted 27 March 2025 PM
Melbourne-based biotech Opthea has announced catastrophic news, with the Phase 3 failure of its eye drug raising the possibility the company could be made to repay money invested in it and go under.
The global COAST Phase 3 trial of VEGF-C and VEGF-D inhibitor OPT-302, or sozinibercept, with 2mg administered intravitreally every four or eight weeks in combination with 2mg of Bayer's Eylea every eight weeks failed to meet its primary endpoint.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.